In spite of their potential to tackle cancer in the long term, CAR-T cell therapies face challenges in terms of pricing, manufacturing and being limited to blood cancer.
‘Chemo mouth’, otherwise known as oral mucositis, has emerged as the most significant adverse event in oncology, according to a National Comprehensive Cancer Network task force.
Seekyo, a startup biotechnology company specializing in the development of ‘smart chemotherapy’ drugs that limit harmful side effects, has raised in excess of €650,000 (US$775K) in bridge funding.
Daiichi Sankyo announced it has entered into a clinical trial collaboration agreement with Merck & Co. to evaluate an investigational lung cancer treatment.
in-PharmaTechnologist presents a roundup of the latest drug delivery research, including bone marrow targeting nanoparticles and an imaging-treatment combo.